about
Gene Therapy Applications to Cancer TreatmentAdvancing Clostridia to Clinical Trial: Past Lessons and Recent ProgressICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells.Tumor-targeting bacterial therapy: A potential treatment for oral cancer (Review)Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors.The role of funding and policies on innovation in cancer drug development.Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction.Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.CD47-retargeted oncolytic adenovirus armed with melanoma differentiation-associated gene-7/interleukin-24 suppresses in vivo leukemia cell growthGenetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapyFuture perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo.Marine Lectins DlFBL and HddSBL Fused with Soluble Coxsackie-Adenovirus Receptor Facilitate Adenovirus Infection in Cancer Cells BUT Have Different Effects on Cell SurvivalHomoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.Oncolytic-adenovirus-expressed RNA interference for cancer therapy.Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.Update on oncolytic viral therapy - targeting angiogenesisClinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy.Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus.A practical guide to the handling and administration of talimogene laherparepvec in Europe.Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.Effect of hypoxia on Ad5 infection, transgene expression and replication.Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer.5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene.Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma.
P2860
Q24792808-295C0766-C0E2-4945-8A8B-899296FA8B30Q26745551-2B4F2801-7281-4480-BAA7-4ACB440397CCQ34178661-5FF9304D-2E8E-4425-83E0-0DBCDF577EF7Q34347463-C4345AE5-4070-4881-BC6D-D852719DA373Q34427510-A41F9D0E-CC34-40DB-AC8A-7A4CCC9BC8F2Q35043106-E2EE179A-4744-4264-8FDC-52A481EB42D0Q35111983-5492FD1C-2426-4DA6-AFD4-EDF2688BB230Q35602147-BA2F9181-5584-47D1-B02F-0B8219F0EE0FQ36072752-2EA4FBF8-FE93-4289-A5EB-B346DA6E5CDDQ36200146-9D7EC041-D11C-4490-BC60-1F4B73408252Q36685435-61D022EC-74D4-4249-8464-13301EBB4DBFQ37069810-F9B00406-9E62-4F55-8B63-979819F4A534Q37267785-20F12CE6-B078-42EA-A092-04F7D0D0A0CEQ37417271-356F499D-7A24-4B3E-AEB7-895FE87D7120Q37448942-E55E1014-71B9-4E54-A8F6-2797E0017DF5Q37679277-9F6D27AC-9978-4F00-A8EE-1A900AA9DFE0Q37721826-6DD2E21E-4E90-4335-B5D5-604A65035886Q37729281-AA8F89D8-C96E-4781-91A1-1B01ECB3D2A1Q37777745-6227EAA1-7847-461D-987E-E2A05AD90A13Q37866781-C2F3EAF3-7352-4883-8F8F-C89A1BDAEF09Q38128561-37FC94A4-E177-4C26-A7E1-B8A4A92F6748Q38630561-9E48FC35-2A06-4CC7-8342-0A9D553A4E13Q39283903-B34B1861-040B-46E1-AC2C-911EE4BA10C9Q39488257-6117671F-CB43-474F-B209-DCCA29287A8DQ39756181-5682D9C2-EF5D-428B-9DA2-A4B92E9752CCQ39778777-0C1AFBFC-64A8-46A9-B3A9-E75157641364Q40024248-356A4905-CFDC-4C1A-8E40-236586285E00Q40080717-02540D3C-C97E-424C-BE97-4778FFF49433Q40416354-5F006198-C668-4770-AA2A-8592A8083F4AQ40462233-EFA19370-D2AC-4064-8888-2C2D83DDCC0FQ40481068-B6DA1E9B-37A2-4C6E-B862-F8207DB2F929Q40601208-3833875E-086B-420B-AB53-8768D1ADCBF4Q45881054-743792FE-EA20-4203-BB6C-49ED7EA49627Q47251747-73092BBB-04BB-40ED-94FC-7D44D2ACD357Q50116255-059CD8DD-BA5A-4933-808F-A7AFF6FB97FAQ55266129-8163F129-80C2-411A-9058-8A3C10717F3B
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Oncolytic biotherapy: a novel therapeutic plafform.
@ast
Oncolytic biotherapy: a novel therapeutic plafform.
@en
Oncolytic biotherapy: a novel therapeutic plafform.
@nl
type
label
Oncolytic biotherapy: a novel therapeutic plafform.
@ast
Oncolytic biotherapy: a novel therapeutic plafform.
@en
Oncolytic biotherapy: a novel therapeutic plafform.
@nl
prefLabel
Oncolytic biotherapy: a novel therapeutic plafform.
@ast
Oncolytic biotherapy: a novel therapeutic plafform.
@en
Oncolytic biotherapy: a novel therapeutic plafform.
@nl
P2093
P1433
P1476
Oncolytic biotherapy: a novel therapeutic plafform.
@en
P2093
David Kirn
Lynda K Hawkins
Nick R Lemoine
P356
10.1016/S1470-2045(01)00618-0
P577
2002-01-01T00:00:00Z